Production (Stage)
Silence Therapeutics plc
SLNCF
$1.59
$0.6263.92%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -1,134.00% | 159.17% | -236.52% | -50.79% | 81.34% |
| Total Depreciation and Amortization | -9.21% | 6.39% | -5.43% | 1.62% | -6.58% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 67.40% | -341.01% | 1,759.85% | -79.85% | -71.60% |
| Change in Net Operating Assets | 201.64% | -1,360.00% | -86.25% | 248.06% | -16.91% |
| Cash from Operations | -34.63% | -91.10% | -314.66% | 67.56% | 1.65% |
| Capital Expenditure | -- | -- | -152.17% | -2,323.68% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 11.08% | 5,537.60% | -243.32% | 113.16% | -26,618.60% |
| Cash from Investing | 11.07% | 5,532.35% | -243.70% | 111.73% | -32,215.83% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 9.53% | 0.00% | -185.29% | -- |
| Issuance of Common Stock | -99.99% | -- | -50.31% | -70.67% | 198,437.31% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 898.37% | 52.37% | -- | -- |
| Cash from Financing | -99.99% | -88.85% | -49.02% | -73.19% | 575,744.16% |
| Foreign Exchange rate Adjustments | 762.86% | 1,210.72% | -494.10% | 70.59% | 95.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -176.34% | 1,757.27% | -267.92% | 78.83% | 853.09% |